news

Mucosis presents data on intranasal RSV vaccine SynGEM® at Vaccines 2014 Conference

Posted: 22 October 2014 | Mucosis B.V.

Mucosis B.V. will present research on its lead intranasal vaccine candidate SynGEM®, a vaccine candidate being researched to prevent infection with respiratory syncytial virus (RSV), at Vaccines 2014…

Mucosis B.V., a clinical stage biotechnology company using a proprietary technology platform to develop next-generation needle-free human vaccines for infectious diseases, will present research on its lead intranasal vaccine candidate SynGEM®, a vaccine candidate being researched to prevent infection with respiratory syncytial virus (RSV), at Vaccines 2014, taking place in London from 20-22 October.

SynGEM® uses Mucosis’s proprietary Mimopath® platform to activate mucosal defenses, allowing more effective protection against infectious diseases. The data presented will include updates on the development of Mucosis’s unique stable prefusion form of the F vaccine antigen, effective against RSV particularly due to the powerful virus neutralizing antibodies it elicits. Results from preclinical studies of SynGEM® in animal models will also be included.

Dr. Kees Leenhouts, Chief Scientific Officer of Mucosis said “We are excited to offer an insight into progress with our lead product, SynGEM®, after the success we’ve achieved in progressing our Mimopath® platform to clinical trial stage. Our prefusion F antigen construct, used in SynGEM®, is potentially able to generate antibodies 40-600 times more potent in virus neutralization compared to the current RSV treatment used in infants. Our new data, demonstrating the vaccine’s immunogenicity, efficacy and safety in animal models, supports the prophylactic potential of SynGEM® across the various target age groups and confirms the value of the unique and stable prefusion-like F form of the antigen we have developed.”

Thomas Johnston, Chief Executive Officer of Mucosis commented, “This is an excellent opportunity to present the evidence behind the breakthroughs we are making in treating infectious diseases. Our advances in both the delivery mechanism and efficacy of RSV vaccines are setting Mucosis apart in this competitive market.”

“SynGEM®: An intranasal prefusion-like RSV F subunit vaccine,” authored by Bert Jan Haijema, Maarten van Roosmalen, Ivy Widjaja, Alan Rigter of Mucosis, Xander de Haan, Peter Rottier of Utrecht University and Kees Leenhouts, will be presented by Dr. Leenhouts, at Vaccines 2014 today.

Related conditions

Send this to a friend